GCLAM therapy shows promise for relapsed/refractory AML

Jun 2nd, 2008 - The phase 1/2 trial evaluated combined G-CSF, cladribine, high-dose cytarabine, and mitoxantrone in adults with relapsed/refractory AML.

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

Dec 7th, 2018 - The EUTOS long-term survival score (ELTS) better discriminates patients for risk stratification than the standard Sokal score, according to findings from an analysis of data from 904 patients treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) who had enrolled in 6 multicenter studies.

Choosing Wisely Champions Initiative

Dec 7th, 2018 - Each year, ASH’s Choosing Wisely Champions Initiative recognizes three practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.

Plenary Scientific Session

Dec 7th, 2018 - The plenary scientific session is a highlight of the annual meeting, where attendees hear presentations of the 6 highest caliber scientific abstracts.

Late Breaking Abstracts & Best of ASH

Dec 7th, 2018 - A preview of the Late Breaking Abstracts and The Best of ASH.

Clinical Practice Guidelines for SCD

Dec 7th, 2018 - ASH is developing new clinical practice guidelines on the management of acute and chronic complications of sickle cell disease

Highlights from Scientific Spotlight Sessions

Dec 7th, 2018 - Scientific spotlight sessions at the ASH annual meeting provided an in-depth review of specific scientific topics.

Dynamic Scientific Panels & Presentations

Dec 7th, 2018 - A look at some of the dynamic scientific panels and presentations including the new frontier of glycobiology and new insights into neonatal hematology

Global Programs & Capacity Building Showcase

Dec 7th, 2018 - The society continues to grow its international influence and help improve hematologic care around the globe.

Look Ahead to 2019

Dec 7th, 2018 - A look ahead to 2019, with ASH President-Elect, Dr. Roy Silverstein

VTE Clinical Practice Guidelines

Dec 7th, 2018 - Six new Clinical Practice Guidelines on Venous Thromboembolism have just been announced.

Rivaroxaban may reduce VTE risk in cancer patients

Dec 6th, 2018 - The CASSINI trial evaluates VTE prophylaxis in ambulatory patients receiving systemic therapy.

Ibrutinib + Rituximab Reportedly Superior to Current Standard of Care in Younger Patients With CLL

Dec 6th, 2018 - The combination of ibrutinib and rituximab provided superior progression-free survival and, after follow-up, superior overall survival, compared with the current standard of care, chemoimmunotherapy (CIT) fludarabine, cyclophosphamide, and rituximab (FCR), in treatment-naive patients younger than 70 years with chronic lymphocytic leukemia (CLL), according to research presented at a late-breakin...

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

Dec 6th, 2018 - Adding daratumumab to standard treatment with lenalidomide and dexamethasone (DRd) reduced the risk of progression or death by 44% among patients with transplant-ineligible newly-diagnosed multiple myeloma, according to an interim analysis of data from the randomized, open-label, multicenter phase 3 MAIA clinical trial

Another Rituximab Biosimilar Passes Lymphoma Test

Dec 6th, 2018 - A rituximab biosimilar demonstrated noninferiority to European (EU)-licensed rituximab (MabThera) in a randomized trial involving patients with low-tumor burden follicular lymphoma

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma

Dec 6th, 2018 - The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

Laurie H. Sehn, MD, MPH, on DLBCL: Trial Results on the Prognostic Significance of MYC

Dec 5th, 2018 - Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses a study by the Lunenburg Lymphoma Biomarker Consortium

Tait D. Shanafelt, MD, on CLL: Results From a Trial of the ECOG-ACRIN Cancer Research Group

Dec 5th, 2018 - Tait D. Shanafelt, MD, of Stanford University, discusses phase III study findings on ibrutinib-based therapy vs standard fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy